q4 adjusted earnings per share $1.98.
sees fy adjusted earnings per share $8.10 to $830 excluding items.
sees fy 2022 adjusted earnings per share $8.10 to $ 8.30.
q3 adjusted earnings per share $1.98.
qtrly adjusted revenue rose 8.8 percent to $292 billion.
compname reports q2 adjusted earnings per share $7.92.
q3 adjusted earnings per share $8.40.
sees fy capital expenditures in range of $2.8 billion to $3 billion.
sees fy 2021 adjusted ebitda $12 billion to $13 billion.
qtrly free cash flow from operations of $18.3 billion, up from $13.5 billion.
qtrly adjusted operating income of $17.3 billion, up 8.1% year over year.
qtrly adjusted revenues of 292.1 billion, an increase of 8.8% versus prior year.
sees fy 2022 revenue growth of 7% to 9%.
q3 adjusted earnings per share $12.00.
expect vaccine volumes to decline about 70% to 80% in 2022, and in-store diagnostic testing volumes will decline 40% to 50%.
sees fy 2021 retail revenue to be plus or minus 1% versus prior year.
